Novartis Supply Chain
Supply Chain of Novartis (NOVN.SW) as of Nov 17, 2026.
Get this data via API
Financial Data API
Supply Chain
-
Last updated:
Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.
Novartis Supply Chain
Correlation: how closely stock prices move together
Same directionNo relationOpposite
168 companies
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.49 | 0.55 | 0.32 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.66 | 0.07 | — | ||
| 2 | -0.66 | — | — | ||
| 3 | -0.78 | -0.60 | — | ||
| 4 | — | — | — | ||
| 5 | — | — | — | ||
| 6 | -0.71 | 0.14 | — | ||
| 7 | Aspen Pharmacare Holdings | — | — | — | |
| 8 | 0.19 | -0.01 | — | ||
| 9 | -0.28 | 0.37 | — | ||
| 10 | Dialogue Health Technologies | -0.72 | 0.27 | — | |
| 11 | -0.79 | 0.01 | — | ||
| 12 | -0.76 | 0.24 | — | ||
| 13 | -0.68 | — | — | ||
| 14 | -0.68 | -0.33 | — | ||
| 15 | -0.81 | -0.05 | — | ||
| 16 | -0.22 | 0.05 | — | ||
| 17 | -0.62 | — | — | ||
| 18 | -0.77 | — | — | ||
| 19 | 0.57 | 0.15 | — | ||
| 20 | 0.65 | 0.34 | — | ||
| 21 | Somerset Therapeutics Limited | 0.75 | — | — | |
| 22 | -0.15 | -0.18 | — | ||
| 23 | -0.72 | 0.03 | — | ||
| 24 | -0.04 | 0.33 | — | ||
| 25 | -0.77 | 0.06 | — | ||
| 26 | -0.57 | 0.23 | — | ||
| 27 | 0.33 | — | — | ||
| 28 | Cellular Biomedicine Group Incorporated | 0.42 | — | — | |
| 29 | -0.74 | -0.70 | -0.45 | ||
| 30 | -0.48 | -0.54 | -0.32 | ||
| 31 | -0.17 | -0.29 | -0.32 | ||
| 32 | -0.71 | -0.44 | -0.30 | ||
| 33 | -0.87 | -0.65 | -0.28 | ||
| 34 | -0.71 | -0.56 | -0.22 | ||
| 35 | -0.73 | -0.31 | -0.22 | ||
| 36 | -0.75 | -0.37 | -0.22 | ||
| 37 | American Software A | -0.79 | -0.55 | -0.20 | |
| 38 | -0.80 | -0.37 | -0.20 | ||
| 39 | -0.49 | -0.54 | -0.19 | ||
| 40 | -0.24 | -0.52 | -0.18 | ||
| 41 | -0.78 | -0.32 | -0.18 | ||
| 42 | -0.63 | 0.20 | -0.17 | ||
| 43 | -0.75 | -0.17 | -0.17 | ||
| 44 | -0.50 | -0.16 | -0.16 | ||
| 45 | -0.06 | -0.28 | -0.16 | ||
| 46 | -0.49 | -0.56 | -0.15 | ||
| 47 | -0.79 | -0.54 | -0.15 | ||
| 48 | -0.75 | -0.50 | -0.15 | ||
| 49 | -0.64 | -0.29 | -0.14 | ||
| 50 | Aukett Swanke Group | -0.56 | -0.46 | -0.13 | |
| 51 | -0.06 | -0.08 | -0.13 | ||
| 52 | -0.84 | -0.42 | -0.12 | ||
| 53 | -0.76 | -0.61 | -0.12 | ||
| 54 | -0.58 | -0.58 | -0.11 | ||
| 55 | -0.45 | -0.14 | -0.11 | ||
| 56 | -0.62 | -0.16 | -0.11 | ||
| 57 | -0.51 | -0.51 | -0.10 | ||
| 58 | 0.14 | -0.24 | -0.10 | ||
| 59 | -0.72 | -0.19 | -0.10 | ||
| 60 | -0.71 | 0.11 | -0.10 | ||
| 61 | -0.30 | -0.32 | -0.10 | ||
| 62 | -0.75 | -0.33 | -0.10 | ||
| 63 | -0.81 | -0.60 | -0.09 | ||
| 64 | -0.76 | -0.49 | -0.09 | ||
| 65 | -0.72 | -0.57 | -0.09 | ||
| 66 | -0.59 | -0.34 | -0.08 | ||
| 67 | -0.76 | -0.17 | -0.08 | ||
| 68 | -0.85 | 0.01 | -0.07 | ||
| 69 | -0.73 | -0.22 | -0.07 | ||
| 70 | -0.77 | -0.24 | -0.07 | ||
| 71 | -0.29 | 0.17 | -0.07 | ||
| 72 | -0.70 | -0.38 | -0.06 | ||
| 73 | -0.60 | 0.04 | -0.06 | ||
| 74 | -0.38 | -0.52 | -0.06 | ||
| 75 | -0.64 | -0.14 | -0.06 | ||
| 76 | -0.63 | 0.17 | -0.05 | ||
| 77 | -0.69 | -0.07 | -0.05 | ||
| 78 | AARTI Industries | -0.49 | -0.55 | -0.05 | |
| 79 | -0.63 | -0.60 | -0.05 | ||
| 80 | -0.74 | -0.02 | -0.04 | ||
| 81 | -0.72 | -0.15 | -0.04 | ||
| 82 | -0.01 | -0.26 | -0.04 | ||
| 83 | -0.53 | -0.49 | -0.04 | ||
| 84 | -0.65 | -0.40 | -0.03 | ||
| 85 | 0.07 | -0.29 | -0.03 | ||
| 86 | -0.53 | -0.27 | -0.02 | ||
| 87 | -0.73 | 0.01 | -0.01 | ||
| 88 | -0.75 | -0.02 | -0.01 | ||
| 89 | BTS Group B | -0.13 | -0.34 | 0 | |
| 90 | -0.88 | 0 | 0 | ||
| 91 | Ayala Pharmaceuticals | -0.76 | -0.03 | 0 | |
| 92 | -0.68 | -0.34 | 0 | ||
| 93 | -0.75 | 0.13 | 0 | ||
| 94 | 0.37 | 0.14 | 0.01 | ||
| 95 | -0.72 | 0.20 | 0.01 | ||
| 96 | -0.23 | -0.45 | 0.01 | ||
| 97 | -0.11 | -0.36 | 0.01 | ||
| 98 | -0.68 | -0.23 | 0.01 | ||
| 99 | -0.79 | 0.19 | 0.01 | ||
| 100 | -0.66 | 0.05 | 0.02 | ||
| 101 | Invitae | -0.81 | 0.10 | 0.02 | |
| 102 | -0.43 | 0.24 | 0.02 | ||
| 103 | -0.63 | 0.01 | 0.02 | ||
| 104 | -0.68 | 0.12 | 0.02 | ||
| 105 | -0.87 | 0.08 | 0.02 | ||
| 106 | Vivimed Labs | -0.47 | 0.13 | 0.03 | |
| 107 | -0.80 | -0.06 | 0.03 | ||
| 108 | -0.82 | -0.04 | 0.03 | ||
| 109 | 0.63 | 0.58 | 0.03 | ||
| 110 | 0.39 | 0.45 | 0.03 | ||
| 111 | -0.69 | 0.17 | 0.03 | ||
| 112 | -0.45 | 0.03 | 0.04 | ||
| 113 | -0.10 | -0.21 | 0.04 | ||
| 114 | -0.37 | -0.13 | 0.04 | ||
| 115 | 0.33 | 0.59 | 0.04 | ||
| 116 | -0.76 | 0.03 | 0.04 | ||
| 117 | -0.55 | -0.11 | 0.05 | ||
| 118 | -0.72 | -0.14 | 0.05 | ||
| 119 | -0.23 | 0.09 | 0.05 | ||
| 120 | -0.68 | -0.02 | 0.05 | ||
| 121 | -0.81 | -0.24 | 0.05 | ||
| 122 | 0.46 | -0.09 | 0.06 | ||
| 123 | Homology Meds | -0.78 | 0.06 | 0.06 | |
| 124 | -0.33 | -0.07 | 0.06 | ||
| 125 | -0.44 | -0.10 | 0.06 | ||
| 126 | -0.68 | 0.03 | 0.06 | ||
| 127 | -0.64 | 0.06 | 0.06 | ||
| 128 | -0.71 | -0.03 | 0.06 | ||
| 129 | 0.07 | 0.27 | 0.07 | ||
| 130 | -0.34 | -0.07 | 0.07 | ||
| 131 | Mauna Kea Technologies O | -0.66 | 0.18 | 0.07 | |
| 132 | -0.13 | 0.54 | 0.07 | ||
| 133 | -0.02 | 0.36 | 0.08 | ||
| 134 | 0.46 | 0.28 | 0.09 | ||
| 135 | Mallinckrodt | -0.63 | 0.23 | 0.09 | |
| 136 | -0.01 | 0.20 | 0.09 | ||
| 137 | Action Construction Equip | -0.16 | -0.19 | 0.09 | |
| 138 | Biocon | -0.20 | 0.21 | 0.09 | |
| 139 | -0.78 | -0.01 | 0.10 | ||
| 140 | -0.59 | 0.09 | 0.10 | ||
| 141 | -0.54 | -0.02 | 0.10 | ||
| 142 | -0.43 | 0 | 0.10 | ||
| 143 | Cipla | 0.18 | 0.18 | 0.10 | |
| 144 | -0.82 | 0.21 | 0.11 | ||
| 145 | -0.07 | 0.01 | 0.12 | ||
| 146 | -0.58 | 0.24 | 0.13 | ||
| 147 | 0.04 | 0.52 | 0.13 | ||
| 148 | Gamida Cell | -0.18 | 0.35 | 0.14 | |
| 149 | USU Software | -0.46 | 0.16 | 0.14 | |
| 150 | -0.74 | 0.10 | 0.14 | ||
| 151 | -0.71 | 0.27 | 0.15 | ||
| 152 | -0.39 | 0.28 | 0.15 | ||
| 153 | -0.48 | 0.22 | 0.15 | ||
| 154 | 0.66 | 0.21 | 0.16 | ||
| 155 | -0.67 | 0.35 | 0.17 | ||
| 156 | -0.81 | 0.28 | 0.17 | ||
| 157 | CardieX | 0.39 | 0.16 | 0.17 | |
| 158 | 0.43 | 0.19 | 0.17 | ||
| 159 | 0.75 | 0.12 | 0.18 | ||
| 160 | 0.47 | 0.67 | 0.18 | ||
| 161 | 0.29 | 0.13 | 0.19 | ||
| 162 | 0.40 | 0.23 | 0.19 | ||
| 163 | -0.49 | 0.34 | 0.20 | ||
| 164 | -0.63 | 0.23 | 0.21 | ||
| 165 | 0.46 | 0.24 | 0.21 | ||
| 166 | Hindusthan National Glass | -0.42 | 0.19 | 0.21 | |
| 167 | 0.28 | 0.59 | 0.23 |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Novartis Stock analysis
What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.
All Key Metrics — Novartis
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth